001     298410
005     20250410112526.0
024 7 _ |a 10.1002/marc.202400739
|2 doi
024 7 _ |a pmid:39887749
|2 pmid
024 7 _ |a 1022-1336
|2 ISSN
024 7 _ |a 0173-2803
|2 ISSN
024 7 _ |a 1521-3927
|2 ISSN
037 _ _ |a DKFZ-2025-00266
041 _ _ |a English
082 _ _ |a 540
100 1 _ |a Schiza, Andriana
|b 0
245 _ _ |a Surfactant-Free Stable Aqueous Shortwave Infrared Amphiphilic π-Conjugated Polymer Nanoparticles.
260 _ _ |a Weinheim
|c 2025
|b Wiley-VCH
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1744277080_31992
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a 2025 Apr;46(6):e2400739
520 _ _ |a Novel amphiphilic π-conjugated polymer nanoparticles tailored to efficiently absorb in the near-infrared II (NIR-II) region of the electromagnetic spectrum (>1000 nm) are presented. To achieve this, it is statistically introduced triethylene glycol substituted bithiophene moieties in various contents into a polymer backbone consisting of alternating thiophene and [1,2,5]thiadiazolo[3,4-g]quinoxaline. Through systematic modifications of monomer ratios, four amphiphilic conjugated polymers are produced. The presence of hydrophilic side chain, like triethylene glycol monomethyl ether, enhanced the polymer's concentration in aqueous media of up to 470%, versus the D-A thiophene and [1,2,5]thiadiazolo[3,4-g]quinoxaline hydrophobic analog polymer, enabling the production of surfactant-free conjugated polymer nanoparticles (CPNs) with higher concentrations (20.3 ppm maximum). Subsequently, the impact of this structural fine-tuning on the optical properties of the polymers and their corresponding CPNs are meticulous investigated. In both cases, it is identified the minimum bithiophene content that maintained the absorption spectra above 1000 nm at significantly higher concentrations. So, these findings contribute to the extensive prospects of these materials in multiple fields including biomedical and optoelectronic applications.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a conjugated polymers
|2 Other
650 _ 7 |a photothermal
|2 Other
650 _ 7 |a polymer nanoparticles
|2 Other
650 _ 7 |a shortwave infrared
|2 Other
650 _ 7 |a sustainable solvents
|2 Other
700 1 _ |a Nega, Alkmini
|0 P:(DE-HGF)0
|b 1
700 1 _ |a Dimitrakopoulou-Strauss, Antonia
|0 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
|b 2
|u dkfz
700 1 _ |a Gregoriou, Vasilis G
|b 3
700 1 _ |a Chochos, Christos L
|0 0000-0002-7783-157X
|b 4
773 _ _ |a 10.1002/marc.202400739
|g p. 2400739
|0 PERI:(DE-600)1475027-2
|n 6
|p e2400739
|t Macromolecular rapid communications
|v 46
|y 2025
|x 1022-1336
909 C O |p VDB
|o oai:inrepo02.dkfz.de:298410
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)b2df3652dfa3e19d5e96dfc53f44a992
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2025
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2024-12-20
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2024-12-20
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2024-12-20
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b MACROMOL RAPID COMM : 2022
|d 2024-12-20
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2024-12-20
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2024-12-20
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2024-12-20
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21